Effects of genetic engineering on the pharmacokinetics of antibodies

Quarterly Journal of Nuclear Medicine

Volumn 43, Issue 2, 1999, Pages 132-139

  Colcher, D ^a   Goel, A ^a   Pavlinkova, G ^a   Beresford, G ^a   Booth, B ^a   Batra, S K ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Antibodies; Antibodies monoclonal; Colon carcinoma xenografts; Immunoglobulin fragments; Monoclonal biosynthesis; Radioimmunodetection

Indexed keywords

ANTIGEN; CHIMERIC ANTIBODY; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MUCIN; RADIOISOTOPE; RECOMBINANT ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; COLON CARCINOMA; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG DISTRIBUTION; GENETIC ENGINEERING; HALF LIFE TIME; HUMAN; RADIOIMMUNOASSAY; REVIEW;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN-ANTIBODY REACTIONS; BINDING SITES, ANTIBODY; CHIMERA; GENETIC ENGINEERING; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN ISOTYPES; METABOLIC CLEARANCE RATE; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS;

EID: 0033058507     PISSN: 11243937     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)